COMPANION DIAGNOSTIC TEST FOR OVARIAN CANCER

Informing treatment for your platinum-resistant ovarian cancer patients through immunohistochemistry staining

Folate receptor alpha (FRα) is a biomarker utilized to determine eligibility for ELAHERE® (mirvetuximab soravtansine-gynx)

Approximately 1 in 3 patients with platinum-resistant ovarian cancer will show FRα expression to qualify for therapy.1 Eligibility for ELAHERE is defined as tumor tissue that shows ≥75% tumor cells staining at 2+/3+ intensity.

Folate receptor alpha (FRα) biomarker determines therapy selection

Approximately 1 in 3 patients with platinum-resistant ovarian cancer (PROC) will show FRα expression to qualify for therapy.1 In the SORAYA study, patients who have received one to three lines of therapy, expressed FRA, and received mirvetuximab soravtansine-gynx demonstrated consistent clinically meaningful antitumor activity and favorable tolerability and safety.1 Eligibility for mirvetuximab soravtansine-gynx is defined as tumor tissue that shows ≥75% tumor cells staining at 2+/3+ intensity.

Myriad offers FOLR1/FRα IHC Testing

To support clinicians in determining FOLR1/FRα status in their ovarian cancer patients, Myriad is proud to offer FOLR1/FRα testing for patients with a diagnosis of epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer.

Patient Eligibility Criteria:

FOLR1/FRα immunohistochemistry (IHC) testing can be ordered for:

  • Patients who have ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer)
  • Patients who do not have a known FRα expression from previous tests
  • Patients who have received at least 1 line of prior systemic therapy

To order FOLR1/FRα IHC Testing for your patients, download the Myriad Test Request Form (TRF).

Paired testing supports ovarian cancer patients

National guidelines support the combined use of germline, genomic, and IHC testing to improve your patients’ outcomes, and Myriad offers a trusted one-stop solution for your testing needs. Our streamlined approach to delivering germline testing, tumor profiling, and companion diagnostic testing ensures you can quickly identify comprehensive treatment options for your patients.

Consider adding the following Myriad Genetics testing for your ovarian cancer patients:

How to test with FOLR1/FRα

FOLR1/FRα results in 7 days or less upon receipt of the sample

Provider completes the test request form

Provider completes the test request form

Myriad Genetics receives the TRF and sends a tumor specimen collection kit to the pathology lab

Myriad Genetics receives the TRF and sends a tumor specimen collection kit to the pathology lab

Tumor sample arrives at Myriad Genetics lab and FOLR1/FRα testing is performed

Tumor sample arrives at Myriad Genetics lab and FOLR1/FRα testing is performed

Results are sent to the ordering provider in the mail

Results are sent to the ordering provider in the mail

Tumor block is returned to the pathology lab immediately after result reporting
(slides will not be returned)

Tumor block is returned to the pathology lab immediately after result reporting
(slides will not be returned)

FOLR1/FRα is run on FFPE sample or tissue with 50-100 tumor nuclei present on 2 slide sections 4 microns thick, placed on unstained, unbaked, positively charged slides.

References:
  1. Matulonis UA, et al., Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023 Jan 30:JCO2201900. doi: 10.1200/JCO.22.01900. Epub ahead of print. PMID: 36716407.